• eTheRNA
  • Follow our progress in developing products that have the potential to transform the future of cancer treatment

Appointment of Chief Financial Officer

Ulrich PlatteNiel (Belgium), 29 May 2019 - eTheRNA immunotherapies NV, the mRNA immunotherapy company, is pleased to announce the appointment of Ulrich Platte as the Company's Chief Financial Officer. Ulrich will join the company on 3rd June 2019.

Ulrich has a broad experience acquired over the last 20 years in different industries including the life sciences, medical device and pharmaceutical sectors. He has held progressively senior positions in financial management roles, including previous CFO roles, and his operational experience encompasses corporate finance, group financial control, strategic planning and M&A. Latterly Ulrich has been engaged in a number of early-stage companies in the life science sector supporting financing and business development activities. He is a graduate in business administration and holds an MBA from the University of Chicago.

Steven Powell, Chief Executive of eTheRNA, said: "I am delighted to welcome Ulrich to the Company. He has extensive financial leadership skills and experience in the sector, which will be of great benefit to eTheRNA. We are at an exciting stage of the Company's development and Ulrich's business experience in international commercial and large-scale research and development organisations will assist the Board and management team in delivering both our strategic and R&D objectives."

###

About eTheRNA Immunotherapies

eTheRNA immunotherapies is a clinical-stage company delivering innovative cancer immunotherapies from its proprietary mRNA-based TriMix platform. eTheRNA’s goal is to commercialise these immunotherapies to deliver long lasting clinical remission to cancer patients. eTheRNA was established in January 2013 as a spin-off from the VUB university in Belgium and is backed by international life science investors.

About TriMix

The TriMix platform, on which eTheRNA’s immunotherapies are based, comprises three mRNAs encoding proteins (caTLR4, CD40L and CD70) that work to deliver optimal activation of dendritic cells. These cells behave as immune response mediators and mobilize the immune system to attack cancer cells through inducing a T-cell response. Clinical proof of concept for TriMix-based immunotherapies has been established through an extensive dataset demonstrating clear clinical benefits in advanced melanoma patients.

Contact information


Telephone: +32 3 369 17 40
Mobile: +32 477 70 97 58